Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern

• Published in: Journal of medical virology 2023-03, Vol.95 (3), p.e28679-n/a
• Main Authors: García‐Pérez, Javier, Bermejo, Mercedes, Ramírez‐García, Almudena, De La Torre‐Tarazona, Humberto Erick, Cascajero, Almudena, Castillo de la Osa, María, Jiménez, Paloma, Aparicio Gómez, Marta, Calonge, Esther, Sancho‐López, Aránzazu, Payares‐Herrera, Concepción, Layunta Acero, Rocio, Vicente‐Izquierdo, Laura, Avendaño‐Solá, Cristina, Alcamí, José, Pérez‐Olmeda, Mayte, Díez‐Fuertes, Francisco
• Format: Article
• Language: English
• Subjects: 2019-nCoV Vaccine mRNA-1273; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Biological Assay; Coronaviruses; COVID-19; COVID-19 - prevention & control; Humans; hybrid immunity; Immune response; Immune response (humoral); Immune system; Immunoassays; Immunoglobulins; Immunological memory; Infections; mRNA; mRNA Vaccines; mRNA‐1273; Neutralization; neutralizing antibodies; Omicron; Respiratory diseases; SARS-CoV-2 - genetics; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; timing of vaccination; Vaccination; Vaccines; Viral diseases; Virology
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.28679

The humoral immune response against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants of concern elicited by vaccination was evaluated in COVID‐19 recovered individuals (Rec) separated 1–3 months (Rec2m) or 4–12 months (Rec9m) postinfection and compared to the response in naïve participants. Antibody‐mediated immune responses were assessed in 66 participants by three commercial immunoassays and a SARS‐CoV‐2 lentiviral‐based pseudovirus neutralization assay. Immunoglobulin (Ig) levels against SARS‐CoV‐2 spike were lower in naïve participants after two doses than in Rec after a single dose (p